ELVN · Enliven Therapeutics, Inc.

The thesis

Enliven Therapeutics has the funding and the Food and Drug Administration (FDA) agreement it needs to start its pivotal leukemia trial, and its shares close 26.8% below their 52-week high. The disclosure of the first patient in ENABLE-2, which the company on 5 November 2026 again guided for before year-end 2026, settles whether the recovery case holds.

The third-quarter report changed little in the case. It reaffirmed the timetable and showed $884.4 million in cash, cash equivalents and marketable securities at 30 September 2026, with runway guided into 2030. The adjusted daily close was $44.79 on 5 November 2026, up from $41.93 on 22 October 2026.

The narrative is maturing: the trial design question closed with the company's 6 October 2026 announcement, and the 5 November 2026 report brought a reaffirmed timetable with no new clinical results. The invalidation level remains a weekly close below $37.50, the price of Enliven's June 2026 public offering.

Bullish and bearish views on Enliven Therapeutics, Inc.

The bull case on Enliven Therapeutics, Inc. (ELVN), in brief: The timetable held at the latest report. The bear case: Good news has not lifted the shares.

Bull case

• The timetable held at the latest report. Enliven said on 5 November 2026 that it is "on track to initiate ENABLE-2 before year-end 2026." The trial will randomize about 450 previously treated chronic myeloid leukemia patients 1:1 to relcobatinib 80 mg daily or an investigator-selected second-generation tyrosine kinase inhibitor (dasatinib, nilotinib or bosutinib).
• One trial could serve two approvals. Per the 5 November 2026 release, major molecular response at week 24 is the primary endpoint and could support accelerated approval. Major molecular response at week 96 is the key secondary endpoint and could support full approval.
• Cash covers the guided plan. The third-quarter 10-Q shows $151.7 million in cash and equivalents and $732.7 million in marketable securities at 30 September 2026. Enliven guides runway into 2030.
• Analyst targets sit well above the shares. MarketBeat counted 10 Buy and 2 Sell ratings with an average target of $75.44 on 5 November 2026. HC Wainwright's target is $73 (19 October 2026), JPMorgan's is $75 (1 October 2026) and Morgan Stanley's is $70 (2 October 2026).
• Early activity supports a controlled test. In the 80 mg Phase 1b cohort, with results cut 10 March 2026 and reported 11 June 2026, major molecular response was 61% among 28 evaluable patients. Among 21 evaluable patients, 48% reached it by 24 weeks. These groups are small and uncontrolled.

Bear case

• Good news has not lifted the shares. The close was $44.75 on 25 September 2026 and $44.79 on 5 November 2026, a stretch that includes two bank initiations, the FDA announcement and a target raise. The three-month change to 5 November 2026 is -24.6%.
• The shares fell on the report. MarketBeat reported a $2.46 decline to $44.79 on 5 November 2026, even though the $0.36 loss per share beat the $0.45 consensus loss.
• Spending has further to rise. Research and development expense was $28.0 million in the third quarter against $18.2 million a year earlier and $29.0 million in the second quarter, all before a 450-patient trial starts. The net loss was $27.7 million against $20.1 million a year earlier.
• The comparator is an approved drug class. ENABLE-2 tests relcobatinib against established second-generation drugs, and the Phase 1b response rates have no control arm. A miss at week 24 would break the clinical case.
• June's share sale sets a visible reference. Enliven priced its June 2026 offering at $37.50, and the 10-Q records 10,533,334 common shares issued in it. MarketBeat lists a sale by the chief financial officer at an average of $38.48 on 19 October 2026, so the shares have recently traded near that price.

Price setup

The adjusted close of $44.79 on 5 November 2026 is 26.8% below the $61.15 52-week closing high. MarketBeat put the 50-day moving average at $47.48 and the 200-day moving average at $42.96 that day, so the shares sit between the two. The 14-day relative strength index is 75.0, up from 33.3 on 22 October 2026, which marks a sharp short-term rebound inside a three-month decline.

Crowding evidence is limited. There is no wide gap above a moving average, and MarketBeat counted volume of 1,585,854 shares on 5 November 2026 against an average of 1,673,929. The earnings date has passed.

Insider selling is small. Scott Garland at an average of $46.67 on 1 October 2026 and 6,018 by chief financial officer Benjamin Hohl under a Rule 10b5-1 plan on 19 October 2026. The largest issuance into strength remains the June 2026 offering, and the third-quarter equity statement shows no at-the-market share sales.

Catalysts, next 30 days

• 9 November to 11 November 2026: Guggenheim Healthcare Innovation Conference, Boston, with a fireside chat and one-on-one meetings. Management can update ENABLE-2 site and enrollment timing here.
• 10 November to 12 November 2026: Stifel Healthcare Conference, New York, with one-on-one meetings.
• 16 November to 19 November 2026: Jefferies Global Healthcare Conference, London, with a fireside chat and one-on-one meetings.
• ~31 December 2026, est.: End of the guided window for the ENABLE-2 start. This falls beyond 30 days, but the case turns on it, and the company has given no exact date. A disclosed first patient or site activation confirms the timetable.

The 5 November 2026 release lists no American Society of Hematology presentation or other new clinical readout among its upcoming events.

What would change the view

The case breaks if Enliven discloses that ENABLE-2 will start in 2027, or if 31 December 2026 passes with no documented start. A serious safety finding for relcobatinib, or a change in the FDA-agreed design, would also break it because the drug carries effectively the entire valuation.

Over the longer term, a miss on the week-24 major molecular response endpoint would end the clinical case. On price, the research condition is a weekly close below $37.50, the June 2026 offering price.

The recovery view gains support if a disclosed first patient comes with closes back above the 50-day moving average, which MarketBeat put at $47.48 on 5 November 2026.

What it trades with

The shares trade mainly on company events, because Enliven is a clinical-stage company with no product revenue and one lead drug. The closest outside read-across is competitor news in previously treated chronic myeloid leukemia, including the second-generation drugs used as ENABLE-2 comparators. Guided runway into 2030 leaves the near-term case less exposed to financing conditions than the trial timetable.